Stephane Allard, MD has over thirty-five years of experience in the pharmaceutical industry. He has played a significant role in successfully bringing major products such as Ambien® and Eloxatin® through the FDA process to the US market. He was President of Synthelabo Research and Vice President of Medical Affairs at Sanofi. Previously, Dr. Allard was President and CEO of Biovest and Chief Medical Officer at EpiCept/ Immune Pharmaceuticals. He received his Medical Doctorate from Rouen Medical College, France and subsequently earned a Diplomate of Clinical Pharmacology and Pharmacokinetics from Pitie-Salpetriere Hospital in Paris, and a Diplomate of CESAM (Certificate of Statistical Studies Applied to Medicine) from Jussieu University in Paris (Paris VI).
Jean Kadouche, PhD was the founder and CEO of MAT Biopharma (MAT). Prior to founding MAT, Dr. Kadouche was Head of the Immunology Department at Saint-Louis Hospital and Européen Georges Pompidou Hospital in Paris. He was a strategic consultant for the monoclonal antibody department of Merck’s International Diagnostic Division and was Licensing Director at Sangstat Medical Europe, Scientific Consultant with Roche Molecular Systems in France and Scientific Consultant at Ortho-Diagnostic of Johnson & Johnson. He received a PhD. from the Pasteur Institute of Paris in Immunology and a MS in Pharmacy.
Copyright © 2022 Alissa Pharma - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.